Artelon

NCT00077584

Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma

NCT00091715

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00319696

Bosentan in Digital Ulcers

NCT00672022

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

NCT00319267

Bosentan in Children With Pulmonary Arterial Hypertension

NCT00319020

Bosentan in Children With Pulmonary Arterial Hypertension Extension Study

NCT00313222

Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension

NCT00319111

Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT00302211

"The VISION Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension"

NCT00319046

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

NCT00310830

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

NCT00360087

A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study

NCT00313196

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)

NCT00391443

BUILD 3: Bosentan Use in Interstitial Lung Disease

NCT00631475

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

NCT00660179

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00709956

Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00723554

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

NCT00709098

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00667823

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00638131

Bosentan Use in Patients With Diabetic Nephropathy

NCT00864201

A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

NCT01106014

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

NCT01112306

ACT-293987 in Pulmonary Arterial Hypertension

NCT01223352

Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

NCT01338415

FUTURE 3 Study Extension

NCT01431716

Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension

NCT01470144

Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension

NCT01389856

Persistent Pulmonary Hypertension of the Newborn

NCT01474109

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01474122

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01841762

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01743001

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01847014

Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument

NCT01739400

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

NCT01983683

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea

NCT02081690

A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

NCT01987895

Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea

NCT02112487

Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH

NCT02425644

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

NCT02471183

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02558231

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

NCT02907177

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT03232073

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

NCT03153137

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT02932410

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT03187678

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03422328

A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

NCT03809650

A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

NCT03689244

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03775421

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

NCT03904693

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04175600

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04273945

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04271475

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04565990

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

NCT05179876

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option